AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY

ANNUAL MEETING PROGRAM — SAN FRANCISCO, CALIFORNIA

Saturday, October 23 - OCTOBER 23-27, 1999
1:00 pm - 5:00 pm Committee Meetings
2:00 - 3:00 pm Program Inspectors
3:00 - 4:00 pm Residency Program Directors
4:00 - 5:00 pm American Osteopathic Board of Dermatology

Sunday, October 24
7:00 am - 3:00 pm In-Training Exam (Resident's Meeting)
8:00 am - 5:00 pm AOBED Exam
8:00 am - 3:00 pm Executive Committee Meeting
8:00 am - 10:00 am Continental breakfast
8:30 - 11:30 am Meeting convenes
7:00 pm - 9:00 pm Gala Welcome Reception

Monday, October 25
9:00 am - 9:10 am Opening Remarks (Gregory G. Papadacos, D.O., Program Chairman)
9:10 am - 10:00 am Update on Malignant Melanoma
(Darrell S. Rigell, M.D., American Academy of Dermatology President)
10:00 am - 10:50 am Hair Loss - TBA (Verne Price, M.D.)
11:00 am - 11:50 am Break
12:00 pm - 12:50 pm A Sweep Through the Immunoallergic Diseases (Daniel Hilbrich, D.O.)
12:50 pm - 1:45 pm Little Known Facts About Sun Damage and Sun Protection
(John R. T. Reeves, M.D.)
1:00 pm - 3:00 pm Alumni Luncheons
3:00 pm - 5:00 pm AOBFD Annual Business Meeting
6:00 pm - 10:00 pm President's Reception/Annual Recognition Banquet
6:00 pm - Reception
7:00 - 9:00 pm Dinner
8:30 - Awards
9:30 - Dessert Reception

Tuesday, October 26
6:45 am - 7:00 am Breakfast
7:00 am - 10:30 am Therapeutics Symposium (James Q. DelRosso, D.O., Moderator)
7:00 - 7:30 TBA (James Q. DelRosso, D.O.)
7:30 - 8:15 What's New in Surgical Dermatology (Ronald Whelan, M.D.)
8:15 - 9:00 Practical Reviews in Dermatology (Howard Matibab, M.D.)
9:00 - 9:45 What's New in Medical Dermatology (Bruce Theirs, M.D.)
9:45 am - 10:00 am Break
10:00 am - 10:50 am Dermatology Pearls (John R. T. Reeves, M.D.)
10:50 am - 11:30 am Dermatologic Surgery - TBA (William C. Chow, D.O.)
12:00 pm - 1:15 pm Lunch Lecture
Great Cases From Osteopathic Institutions
(Cindy E. Hoffman, D.O., Moderator)
1:30 pm - 1:50 pm TBA (Mark Horowitz, D.O., Pontiac Osteopathic Hospital)
1:50 pm - 2:30 pm Occupational Skin Diseases
(Raymond Schwab, D.O., Brooke Army Medical Center)
2:10 pm - 2:30 pm P.E.T. Scan In The Management Of Head & Neck Malignoma
(Brent Goodsell, D.O., KCOM-NE Regional Medical Center)
2:30 pm - 2:50 pm Pseudolymphoma Within A Tattoo
(Brian Mathys, D.O., Cuyahoga Falls General Hospital)
2:50 pm - 3:10 pm Systemic Steroid Use (Daniel J. Abraham, D.O., Pontiac Osteopathic Hospital)
3:10 pm - 3:20 pm Break
3:25 pm - 3:55 pm TBA (Gregg Wilentz, D.O., NSU-North Broward Hospital)
3:55 pm - 4:05 pm Nasopharyngeal Carcinoma & Diffuse Scleroderma (Deborah J. Daly, D.O., St. Barnabas Hospital)
4:05 pm - 4:25 pm The Use Of Lasers In Dermatology In The 90's
(Shawn Stodink, D.O., NSU-North Broward Hospital)
4:25 pm - 4:45 pm Hyperhidrosis (Kathryn Balskus, D.O., Grandview Hospital & Medical Center)

Wednesday, October 27
6:45 am - 7:00 am Breakfast
7:00 am - 7:45 am Botulin - Practical Clinical Tips (Richard G. Glogau, M.D.)
7:45 am - 8:15 am Great Cases (Jere J. Mammino, D.O.)
8:15 am - 9:00 am What's New In Cutaneous Laser Surgery (Roy C. Grekin, M.D.)
9:00 am - 10:00 am Dermatopathology Scholarship Case Presentations (Michael Palko, M.D., Moderator)
10:00 am - 10:15 am Break
10:15 am - 11:00 am 1999 - Ten Tips For Coding Concerns (Vernell St. John)
11:00 am - 11:45 am Dermatology - TBA (Richard B. Odom, M.D.)
12:15 pm - Adjourn

AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY

AOCD Newsletter
Volume 18 Number 43
Summer 99

Calendar of Events

1999:
Annual Meeting
October 24-28
San Francisco, CA

2000:
Midyear Meeting
January 26-29
Banff, Canada
1999 Midyear Meeting Highlights

The 1999 AOCID Midyear Meeting was held in Indian Wells, CA, February 3-6. The academic program led by Dr. Cindy Hoffman was superbly organized. The presentations were outstanding and provided many pearls of knowledge.

The social program began on Wednesday with a moonlight poolside reception. Thursday afternoon many attendees and their guests participated in an AOCID golf outing at the Indian Wells Golf Resort. Although it was a little cool and damp, even though they say "it never rains in California", everyone enjoyed their outing. On Friday, we took a historic covered wagon trail ride and learned about the biology and medicinal botany of the desert. A delightful and delicious country BBQ accompanied by the sounds of a strolling country serenade capped the day.

Our next winter meeting will be held at the beautiful Banff Springs Hotel in Banff, Alberta, Canada. The hotel is regarded as one of the most romantic locations in the world. You can view the hotel on the Internet (www.discovertherockies.com/photogallery/10-3.html or www.skilouise.com/lodgings/banff_springs_hotel/). A favorable exchange rate also should make this trip a great value.

If you have any suggestions, comments, or concerns regarding the midyear sites, please feel free to contact me by fax (314-831-9310) or call AOCID Executive Director Becky Mansfield at 800-449-2623.

Robert E. Schwarze, D.O.
Chairman, Site Committee

Osteopathic Legislative Hotline

Through the efforts of the Auxiliary to the AOA and the AOA the Osteopathic Legislative Hotline has been rejuvenated. The weekly message is updated by the Washington office of the AOA. Every Thursday the toll-free Hotline provides cutting-edge policy updates about policies affecting the osteopathic community.

Call 1-800-560-6229 to learn what Washington policymakers are doing and what you can do to make the D.O. Difference!

Welcome to San Francisco!

This year’s AOCID Annual Meeting will be held October 24-27 in one of America’s most picturesque and culturally diverse cities, San Francisco.

San Francisco has much to offer. Fisherman’s Wharf, Alcatraz, Golden Gate Bridge, Union Square, Pier 39 and Chinatown to name a few! Downtown has one of the largest varieties of shopping one could ask for. The Welcome Reception will be held at the top of the Bank of America building allowing a panoramic view of all the Bay area. Surely, making for a memorable evening.

The didactic program will be a combination of both medical and surgical topics given by well-known D.O. and M.D. colleagues.

We look forward to offering a wonderful professional experience and allowing a beautiful setting in which to enjoy family and friends. See you there!

Gregory G. Papadeas, D.O.
Program Chairman
Regulation of In-Office Procedures

The practice of dermatology has long been thought of as an office based delivery of care system. This concept may be about to change due to new regulations requiring physicians without hospital privileges to complete a credentialing process for surgical and anesthesia procedures delivered in an office setting. In addition, physicians may be required to demonstrate that they have routinely updated these skills, and in turn their medical equipment as well as ensured proper training of all staff members.

As a dermatologist I will continue to oppose the regulation of in-office procedures. My obvious concern is that of costs as the costs of providing care will definitely rise: This is particularly true if new equipment becomes mandatory. Another concern is that some dermatologists cannot afford to comply and will be forced to close their offices. Although the primary objective is to protect the patient, these laws clearly benefit anesthesiologists as well as physicians with hospital privileges on one hand, and negatively impact the groups of dermatologists not using the hospital.

I realize that this is a controversial issue for many physicians whose practices may be affected by the outcome. How does your state stand on this issue?

The Editor
AOCN Newsletter
Ronald C. Miller, DO, FAOCN

AOCD Poster Project

During the past several years the Public Relations Committee has reviewed several ideas for increasing public awareness of Osteopathic Dermatologists. One idea which has been presented by numerous members of our college has been a poster similar to the ones produced by the AAD. Although we do not wish to compete with their award winning posters, we feel a poster promoting osteopathic dermatologists and their concern about (and ability to treat) skin cancer would benefit our membership.

The photo above was selected by the committee as a possibility for the poster. A proposed slogan for it is "Practicing sun protection, especially from 10 a.m. until 4 p.m., is very important in preventing some skin cancers and sun damage".

Please fax (660-626-2714) or mail (P.O. Box 7525, Kirksville, MO 63501) your comments and suggestions to the AOCD national office. We would welcome any suggestions our members have for ways to increase awareness of our members.

Public Relations Committee

The A.O.C.D. was well represented at the Washington State Osteopathic Medical Association meeting at the Columbia River Gorge as Drs. Lloyd Cleaver, Robert Schwarze and Michael Scott teamed up for a Dermatology Symposium. Dr. Scott was voted in as incoming president of WOMA and another highlight was Dr. Cleaver's catch of a spectacular ten foot long Sturgeon fish which was released back into the river.

In addition to his election as President-elect, Dr. Scott received the Washington Osteopathic Medical Association "Physician of the Year" Award.

Left to Right: Drs. Lloyd Cleaver, Robert Schwarze and Michael Scott
1999 Annual Meeting

Dr. Gregory Papadeas, Program Chair and President-Elect, has put together an excellent program for the upcoming AOCB Annual Meeting held in conjunction with the 104th Annual AOA Convention and Scientific Seminar. Opening the program on Monday morning, October 25 at 9:00 a.m. will be Dr. Darrell S. Rigell, President of the American Academy of Dermatology.

There will be a few changes in the meeting format this year. The Annual Business Meeting will be held on Monday at 3:00 p.m. following the Alumni lunches. This will be held in the San Francisco Marriott Hotel which will also serve as the location of many of the alumni lunches. On Tuesday, there will be a noon lunch with the "Great Cases of Osteopathic Institutions" moderated by Dr. Cindy Hoffman. This will be held in the Moscone Convention Center in room 306 separate from our lecture hall (304). Lectures will be completed at noon on Wednesday.

The AOA will hold its second National Symposium Women's Health on October 23 at the Palace Hotel prior to the opening of the Annual Meeting. The theme for the 104th session will be "Osteopathic Medicine-Healthy Women: the Key to Healthy Families-Leading into the New Millennium (Phase II)."

Resident's Corner

Meet our Resident

I. Barbara J. Baughman Cortez, DO, a second year resident at Grandview Hospital, graduated from the West Virginia School of Osteopathic Medicine on May 31, 1997, where I was active in the Student Osteopathic Medical Association and student government. I completed a traditional rotating internship from Grandview Hospital in July 1998. My interests at this time include exercising when possible, and mystery novels.

Certificate of Added Qualification in MOHS and Dermatopathology

Any AOA Board Certified dermatologist interested in obtaining subspecialty certification of added qualification in MOHS or dermatopathology may qualify for the exam by completing a twelve month AOA approved formal training program.

Applicants not so trained may apply for AOA approval of training if they received concentrated sub-specialty training in their residency or have extensive practice experience. This "practice-pathway" to qualify to sit for the exam will expire on April 1, 2000 for MOHS and April 1, 2001 for Dermatopathology. After these dates, only formal sub-specialty training will be accepted. Please contact the AOCB Executive Director for an application packet if interested.

Change of Address

For those residents who will complete training in July, please do not forget to notify the AOCB office of your new addresses and phone numbers as soon as possible. Be sure to consider your e-mail addresses when you report an address change.

Midyear Meeting 2000

"Intent to Lecture" forms for the 2000 Midyear Meeting in Banff, Canada are due to Dr. Robert Schwarze no later than Friday, July 30. Speaking slots are assigned on a "first come - first selected" basis. These can be faxed (341-831-9301) or mailed (1120 Graham Road, Florissant, MO 63031-8031) to his office.

Annual Reports

Resident and program director annual report forms and papers are due 30 days after completion of the contract year. As a reminder, all forms submitted to the AOCB should be typewritten and completed in their entirety. Incomplete forms will be returned to the resident.
Amy E. Goldstein, D.O. (resident at St. Barnabas) had the following articles accepted/published: "A Recurrent Rash with Blisters", published in Patient Care, May 15, 1999. "Orf" accepted by Consultant PhotoClinic.


Melinda Greenfield, D.O. (resident at St. Barnabas) presented a poster on "Basal Cell Nevus Syndrome" at the AAD in New Orleans.

Scott J.M. Lim, D.O. was recently voted by the family practice residents at Hamot Medical Center, Erie, PA to receive the "Roland E. Miller, MD, Annual Teaching Award" for 1999. This award was presented at their graduation dinner. Dr. Lim currently is in solo private practice in Erie, and a Clinical Assistance Professor in Dermatology at the Lake Erie College of Osteopathic Medicine and also a Clinical Instructor at the Philadelphia College of Osteopathic Medicine.

On behalf of Dermik Laboratories, the St. Barnabas Dermatology Residency invites all AOCDS members to New York City to a welcoming reception on the occasion of the American Academy of Dermatology Summer Meeting on Thursday, July 29, 1999 from 5 to 7 pm at the New York Hilton, Petit Trianon Room. Please fax RSVP to Michael Strothbach by July 16, 1999. 610-454-3578.

The NYCOM/St. Barnabas Dermatology Residency Program had a display of poster exhibits at the recent American Osteopathic College of Dermatology Midyear Meeting in Palm Desert, California, where Cindy Hoffman, D.O. chaired the program.

News From Toma

At their recent annual meeting, members of the Texas Osteopathic Medical Association elected Bill V. Way, D.O., President-elect of their organization. Dr. Way practices in Duncanville, Texas and has been involved in the AOCDS residency programs as a program director.

Above: Amy Goldstein (1st yr). Nancy Spinelli (2nd yr), Cindy Hoffman (3rd yr). Deborah Daly (2nd yr), and Cindy Lim (2nd yr).
American Osteopathic College of Dermatology

1998-1999

Corporate Supporters

DIAMOND
AmeriPath, Inc.
C & M Pharmaceul. Inc.
Janssen Pharmaceutica, L.P.
Medicis Pharmaceutical, Inc.

PLATINUM
Westwood (Bristol-Myers-Squibb) Pharmaceuticals

GOLD
Allergan
Dermatopathology Lab of Central States
Dermik Laboratories, Inc.
Ferdale Laboratories, Inc.
Galderma Laboratories, Inc.
Glaxo Dermatology
Oelkess Pharmaceutical, Inc.
Ortho - McNeil Pharmaceutical Corporation
Roering, Pfizer, Inc.
Schering Laboratories
SmithKline Beecham Pharmaceuticals
Stiefel Laboratories
Novartis Pharmaceuticals

SILVER
Merck & Company

Practice Opportunity
Private, multi-specialty internal medicine practice seeks independent minded clinical dermatologist. Are you tired of working for a hospital or HMO? Do you want to control your own destiny? This ten-member practice, located in a very scenic section of Upstate New York State, might be just what you are looking for! We are currently made up of Primary Care and the following sub-specialties: Cardiology, Endocrinology, Oncology, GI, Rheumatology, Geriatrics and Occupational Medicine.

The practice is more than large enough to support a clinical dermatologist on its own. Demand also exists for dermatology in the rest of the medical community. Our facilities include on site laboratory, Multi-light, Silk-light, infusion center, DEXA scanner and a cardiovascular lab. We will provide salary protection, excellent benefits and partnership potential to the right individual.

This is a golden opportunity to work for yourself in a limited managed care environment. If you need the security (and loss of control) of working for a large health care organization, this is not the place. If, however, you want the opportunity to reward yourself for your hard work, please contact us!

David A. Frey
Administrator
Internal Medicine Associates of the Southern Tier, PC
200 Madison Avenue 3rd Floor
Elmira, NY 14901
(607) 767-4108
Extends The Therapeutic Utility
Of Benzoyl Peroxide Therapy

From Stiefel, the 160-year leader in dermatology and the first name in benzoyl peroxide, a unique and aggressive, yet agile therapy for acne vulgaris, featuring the proven, patented[^7] Hydrophase gel formulation that's made Brevoxyl the fastest growing prescription benzoyl peroxide medication.^

Delivers The Efficacy Of 20% BPO
With An 8% Concentration^1

- Reduces lesion count

![Graph](image1)

Mean inflammatory lesion counts after 8 to 11 weeks of treatment with Brevoxyl-8 (C) or benzoyl peroxide in 20% concentration (C)

- Results in impressive global improvement^1

Brevoxyl-8 provided similar global improvement when compared to benzoyl peroxide 20% throughout all time points studied.

Provides The Proven Solution To
Overcome Particulate Irritation

Patented delivery system dissolves benzoyl peroxide crystals into a solution on the skin, helping avoid particulate irritation—a primary source of adverse events in traditional BPO therapy.

Percent of Patients with Excellent
Overall Tolerance Scores^2

- Is proven to be considerably less irritating^2
- Exhibits a high level of patient acceptance, with five times fewer interruptions in treatment due to irritation^2

Research in Dermatology

[^7]: U.S. Patent No. 6,232,668
[^1]: Results demonstrated by significantly less erythema and peeling with patients also reporting less burning.
BREVOXYL® ... Your Growing Team Of Products Formulated For Success

- Efficacy equal to higher benzoyl peroxide concentrations
- Low discontinuation rate with irritation levels comparable to a 2 1/2% benzoyl peroxide
- High level of physician and patient acceptance
- Available in 4% and 8% gel, as well as 4% and 8% cleansing lotion providing full treatment range and flexibility
- Promoted exclusively to dermatologists

For more information or to request product samples, contact Stiefel Laboratories, Inc. 1761 Allisonville Circle, Canal Cedro, FL 33304 or call Toll Free 1-888-STIEFEL (784-5356)

In two separate studies, Brevoxyl Gel (benzoyl peroxide) 4% was shown to be comparable to Benzamycin in efficacy and patient tolerability.

HYDROPHASE GEL
Brevoxyl-4
(benzoyl peroxide 4%)
ACNE WASH FOR TOPICAL USE

Brevoxyl-8
(benzoyl peroxide 8%)
ACNE WASH FOR TOPICAL USE

Brief Summary Of Prescribing Information

INDICATIONS AND USAGE: Brevoxyl Cleansing Lotions and Brevoxyl Gels are indicated for use in the topical treatment of mild to moderate acne vulgaris. Brevoxyl Cleansing Lotions and Brevoxyl Gels may be used as adjuvants in acne treatment regimens including antibiotics, retinoic acid products, and salicylic acid containing preparations.

CONTRAINDICATIONS: Brevoxyl Cleansing Lotions and Brevoxyl Gels should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients in the products.

PRECAUTIONS: General — For external use only. Avoid contact with eyes and mucous membranes.

CAUTION: Use only as directed. Store at controlled room temperature 15°-30°C (59°-86°F).

HOW SUPPLIED: Brevoxyl-4 Cleansing Lotion and Brevoxyl-8 Cleansing Lotion are supplied in 297 g (10.5 oz) plastic bottles.

Brevoxyl-4 Cleansing Lotion
NDC 0140-2810-05
Brevoxyl-8 Cleansing Lotion
NDC 0140-2810-05

Brevoxyl-4 Gel and Brevoxyl-8 Gel are supplied in 42.5 g (1.5 oz) and 90 g (3.1 oz) tubes.

Brevoxyl-4 Gel
42.5 g tube NDC 0140-2374-06
90 g tube NDC 0140-2374-06

Brevoxyl-8 Gel
42.5 g tube NDC 0140-2384-06
90 g tube NDC 0140-2384-06

U.S. Patent No. 4,823,900

1 Market Measures Study, 1992
2 2,000 Pharmacists Market Drug Survey; December 1993
3 Data on file, Stiefel Laboratories, Inc.

Brevoxyl® and Stiefel are registered trademarks of Stiefel Laboratories, Inc.

Copyright 1996, Stiefel Laboratories, Inc.

Stiefel Laboratories, Inc.
41-220-7 1036 9X-06-96 USA-F

Research in Dermatology
Monodox® provides comparable efficacy to minocycline.¹⁴
(Jill may be very stressed about her big presentation, but at least her skin looks good)

Monodox has a minimal risk of CNS side effects.⁵
(Jill can drive safely to the presentation without worrying about becoming dizzy)

Monodox has a minimal risk of hyperpigmentation.⁶
(Jill never looked better in front of her clients)

Monodox is an economical choice.⁷
(Jill's going to treat herself to a well deserved reward)

Prescribe Monodox.
(Jill's one happy patient)

The tetracycline family of antibiotics is useful adjunctive therapy for the treatment of severe acne. Monodox is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. Photosensitivity has been observed in some individuals taking tetracycline. Treatment should be discontinued at first evidence of skin erythema.

Please see following page for references and brief summary of prescribing information for additional warnings, precautions, and adverse reactions.

H1011/1(S55A)
**Monodox**

**Doxycline Monohydrate Capsules**

**SUMMARY**

**INDICATIONS AND USAGE:** Doxycline is indicated for the treatment of the following infections:
- Respiratory infections: Pneumonia, bronchitis, and sinusitis caused by *Staphylococcus aureus*, *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Haemophilus parainfluenzae*.
- Skin and skin structure infections caused by *Staphylococcus aureus* and *Streptococcus pyogenes*.
- Pelvic inflammatory disease caused by *Chlamydia trachomatis* and *Neisseria gonorrhoeae*.
- Urogenital tract infections caused by *Chlamydia trachomatis*.
- Otitis media caused by *Streptococcus pneumoniae*, *Moraxella catarrhalis*, and *Haemophilus influenzae*.

**CONTRAINDICATIONS:** Doxycline is contraindicated in patients who are hypersensitive to any of the tetracyclines.

**WARNINGS:** The use of doxycycline is associated with the risk of photosensitivity reactions, which can be severe and may require discontinuation of the drug. Patients should avoid prolonged sun exposure and use sunscreen while on therapy. Doxycycline may also cause excretion of a yellow/brown discoloration of teeth. If this occurs, bleaching may be considered.

**PRECAUTIONS:** Doxycycline can cause phototoxicity and photosensitivity reactions. Patients should avoid prolonged sun exposure and use sunscreen while on therapy. Doxycycline may also cause excretion of a yellow/brown discoloration of teeth. If this occurs, bleaching may be considered.

**ADVERSE REACTIONS:** Doxycycline is generally well tolerated. Common side effects include gastrointestinal disturbances, skin reactions, and photosensitivity. Severe reactions are rare but may include hypersensitivity reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

**REFERENCES:**

**Manufactured by:** Oladex Pharmaceuticals Inc., 4000 Madison Rd, Cincinnati, OH 45242.

**References:**

**Order Form:**

- **Store A:** Controlled Room Temperature 15°-30°C (59°-86°F). Protect from direct sunlight. 3055-239-07

Cautions: Federal law prohibits dispensing without prescription.